Intensity-Modulated Radiation Therapy Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

IMRT Versus 3DCRT for Locally Advanced Rectal Cancer, Prospective Phase II Study.
Conditions: Rectal Cancer; Radiotherapy; Toxicity Due to Radiotherapy Interventions: Radiation: Intensive Modulated Radiation Therapy; Radiation: 3-Dimension Conformal Radiation Therapy Sponsors: Rabin Medical Center Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 7, 2023 Category: Research Source Type: clinical trials

Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity Modulated Radiation Therapy:10-Year Outcome and Late Toxicity, Quality of Life
Conditions: Nasopharyngeal Carcinoma Sponsors: Fujian Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials

New-mode Clinical Target Volume Delineation of Nasopharyngeal Carcinoma
Conditions: Nasopharyngeal Carcinoma by AJCC V8 Stage Interventions: Radiation: New-mode reduce-volume target IMRT Sponsors: Fujian Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 23, 2023 Category: Research Source Type: clinical trials

Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy
Conditions: Nasopharyngeal Carcinoma; De-escalation Therapy Interventions: Drug: Cisplatin-based induction chemotherapy; Drug: Full course of PD-1/PD-L1 blockades; Radiation: Reduced-dose IMRT; Radiation: Standard-dose IMRT; Drug: Concurrent Chemotherapy Sponsors: Sun Yat-sen University; First Affiliated Hospital, Sun Yat-Sen University; Affiliated Cancer Hospital& Institute of Guangzhou Medical University; Guangdong Provincial People ' s Hospital; Second Affiliated Hospital, Sun Yat-Sen University; The fifth Affiliated Hospital of Guangzhou Medcial University; Zhongshan People ' s Hospital, Guangdong, China; Hunan Cancer ...
Source: ClinicalTrials.gov - October 20, 2023 Category: Research Source Type: clinical trials

Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer
Conditions: Head and Neck Squamous Cell Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Laryngeal Squamous Cell Carcinoma; Oral Cavity Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma; Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage III Hypopharyngeal Carcinoma AJCC v8; Stage III Laryngeal Cancer AJCC v8; Stage III Lip and Oral Cavity Cancer AJCC v8; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage IV Hypopharyngeal Carcinoma AJCC v8; Stage IV Laryngeal Cancer AJCC v8; Stage IV Lip and Or...
Source: ClinicalTrials.gov - October 16, 2023 Category: Research Source Type: clinical trials

Phase II Randomized Study of Hypofractionated Versus Conventional Radiotherapy
Conditions: Laryngeal Carcinoma Interventions: Radiation: LT-SABR; Radiation: IMRT Sponsors: University of Texas Southwestern Medical Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 12, 2023 Category: Research Source Type: clinical trials

Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
Condition: Head and Neck Cancer Interventions: Drug: Xevinapant; Drug: Cisplatin; Radiation: intensity-modulated radiation therapy (IMRT) Sponsors: EMD Serono Research & Development Institute, Inc.; Merck KGaA, Darmstadt, Germany Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials

Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
Conditions: Head and Neck Cancer Interventions: Drug: Xevinapant; Drug: Cisplatin; Radiation: intensity-modulated radiation therapy (IMRT) Sponsors: EMD Serono Research& Development Institute, Inc.; Merck KGaA, Darmstadt, Germany Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials

SAHARA-04 : Adaptive Radiotherapy in Hypersensitive Patients and High Locoregional Risk Breast Cancer With ETHOS Technology
Condition: Breast Cancer Interventions: Radiation: Treatment ETHOS radiotherapy; Radiation: Conventional IMRT Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials

SAHARA-04 : Adaptive Radiotherapy in Hypersensitive Patients and High Locoregional Risk Breast Cancer With ETHOS Technology
Conditions: Breast Cancer Interventions: Radiation: Treatment ETHOS radiotherapy; Radiation: Conventional IMRT Sponsors: Institut du Cancer de Montpellier - Val d ' Aurelle Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials

Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas)
Condition: Pancreatic Adenocarcinoma Intervention: Radiation: Dose-Painted Intensity Modulated Radiotherapy Sponsor: Cancer Trials Ireland Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 6, 2023 Category: Research Source Type: clinical trials